Market Trends of High Content Screening Industry
Flow Cytometry is Expected to Hold a Significant Market Share Over The Forecast Period
Flow cytometry is used in many research and clinical laboratories. Previously, flow cytometry was significantly restricted because of its limitations in handling scores of samples. However, with unparalleled advances in cell-based analysis and screening in recent years, this technique has been utilized as a powerful screening tool.
Various studies are done that deploy flow cytometry in research laboratories which are expected to propel the segment utility. Its primary users are immunologists and hematologists, who use it for cell sorting and analysis. For instance, a research study published in Frontiers in Immunology in February 2022, was conducted to develop a flow cytometric procedure for quantitative expression profiling of surface antigens on blood leukocyte subsets that are standardized across multiple research laboratories. The process, bioinformatics pipeline, and improved flow panels enable benchmarking new antibody clones to established CD markers and mapping the expression patterns of mAb clones with HLDA approval to CD markers. The advantages of flow cytometry, like the high-speed quantitative and high-content analysis of cells, make the technique an attractive technology for drug discovery applications. The rising research studies using flow cytometry and its advantages are expected to propel the segment growth during the analysis period.
Various market players are engaged in strategic initiatives such as product launches, partnerships, and innovation in technology to develop an advanced solution in the flow cytometry segment. For instance, in March 2022, Beckman Coulter Life Sciences launched the CellMek SPS solution to manual sample preparation and data management bottlenecks in clinical flow cytometry. The fully automated sample preparation system (SPS) offers on-demand processing to assist laboratories in enhancing their capabilities. Such launches are expected to propel the segment growth during the forecast period.
Therefore, flow cytometry is becoming an ideal tool, particularly in an environment where primary cell-based assays are increasingly being deployed to monitor drug responses. The increasing use of phenotypic cell-based assays in drug discovery and the need to monitor drug responses are major factors for the growth of flow cytometry. Therefore, the usage is expected to increase in the coming years. Additionally, the utilization of flow cytometry in the detection of cancer is further augmenting the growth of the segment.
North America is Expected to North America is Expected to Hold a Significant Market Share Over The Forecast Period
North America is expected to have a significant market share over the forecast period in the high-content screening market due to the growing research and development activities by pharmaceutical companies, the growing prevalence of chronic diseases in the country, and increasing technological advancements in high-content screening methods.
According to the American Cancer Society's 2022 report, about 1,918,030 new cancer cases were estimated in 2022 in the United States. Also, according to the Canadian Cancer Statistics November 2021 report, an estimated 2 in 5 Canadians were likely to be diagnosed with cancer in their lifetime. It stated that an estimated 229,200 Canadians was predicted to be diagnosed with cancer in 2021. Thus, the high prevalence of cancer is expected to boost the high-content screening market in the region for providing the best safety and efficacy to the manufactured drugs.
The increasing number of cardiovascular diseases among patients further increases the need and demand for effective therapeutics for various inherited cardiovascular conditions. For instance, the prevalence rate of heart failure in the United States is 6 million, which is 1.8% of its total population, as reported by the American Heart Association in 2021. This is expected to be one of the major driving factors for the growth of the market studied in the United States.
Therefore, owing to the factors mentioned above, such as the high prevalence of cancer and chronic diseases boosting the demand for high-content screening for boosting drug efficacy, the high-content screening market is expected to witness substantial growth in North America during the forecast period.
